健康な成人におけるV114の安全性および免疫原性（V114-019/PNEU-AGE）

基本情報

NCT ID

NCT03950622

ステータス

完了

試験のフェーズ

第3相

試験タイプ

介入

目標被験者数

1,205

治験依頼者名

Merck Sharp & Dohme LLC

概要

The purpose of this study is to 1) evaluate the safety and tolerability of V114 and 2) to compare the immune responses of the 15 serotypes contained in V114 with V114 versus Prevnar 13™. The primary hypotheses are that 1) V114 is noninferior to Prevnar 13™ as measured by the serotype specific opsonophagocytic activity (OPA) geometric mean titers (GMTs) for 13 shared serotypes at 30 days postvaccination and that 2) V114 is superior to Prevnar 13™ as measured by serotype-specific OPA GMTs for 2 unique serotypes in V114 at 30 days postvaccination.

対象疾患

介入

依頼者（Sponsor）

実施施設 (5)